Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration
Martina Ott, Karl-Heinz Tomaszowski, Anantha Marisetty, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Glioma targeted therapy: insight into future of molecular approaches
Keyang Yang, Zhijing Wu, Hao Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 483
Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy
Fatima Khan, Lizhi Pang, Madeline Dunterman, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 1
Open Access | Times Cited: 187
Glial and myeloid heterogeneity in the brain tumour microenvironment
Brian M. Andersen, Camilo Faust Akl, Michael A. Wheeler, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 12, pp. 786-802
Open Access | Times Cited: 144
Immunotherapy for glioblastoma: the promise of combination strategies
Mathilde Bausart, Véronique Préat, Alessio Malfanti
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 144
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Víctor A. Arrieta, Crismita Dmello, Daniel J. McGrail, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 2
Open Access | Times Cited: 125
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma
Alessandra De Leo, Alessio Ugolini, Xiaoqing Yu, et al.
Immunity (2024) Vol. 57, Iss. 5, pp. 1105-1123.e8
Closed Access | Times Cited: 57
The immune landscape of common CNS malignancies: implications for immunotherapy
Martina Ott, Robert M. Prins, Amy B. Heimberger
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 11, pp. 729-744
Closed Access | Times Cited: 74
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Natalia Sauer, Wojciech Szlasa, Laura Jonderko, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9958-9958
Open Access | Times Cited: 53
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them
Karl J. Habashy, Rana Mansour, Charbel Moussalem, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 6, pp. 976-987
Open Access | Times Cited: 46
LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
Rebecca Ibrahim, Khalil Saleh, Claude Chahine, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1878-1878
Open Access | Times Cited: 24
Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy
Sergej Kudruk, Connor M. Forsyth, Michelle Z. Dion, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 8
Closed Access | Times Cited: 13
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy
Aleksei A. Stepanenko, Anastasiia O. Sosnovtseva, M. P. Valikhov, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study
Kunming Cheng, Huan Zhang, Qiang Guo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
Zoya Kurago, Gang Guo, Huidong Shi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers
Nazanin Tatari, Shahbaz Khan, Julie Livingstone, et al.
Acta Neuropathologica (2022) Vol. 144, Iss. 6, pp. 1127-1142
Open Access | Times Cited: 26
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Yang Liu, Wei Xu, Mingxue Li, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 4, pp. 1438-1466
Open Access | Times Cited: 14
Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer
Xiang Gong, Chao Zheng, Ying Cai, et al.
Journal of Controlled Release (2024) Vol. 367, pp. 637-648
Closed Access | Times Cited: 5
New Approaches to Glioblastoma
Mustafa Khasraw, Yoko Fujita, Catalina Lee-Chang, et al.
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 279-292
Open Access | Times Cited: 30
Targeting Immunometabolism in Glioblastoma
Aditya Mohan, William H. Tomaszewski, Aden Haskell-Mendoza, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 27
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Kirit Singh, Kristen A. Batich, Patrick Y. Wen, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 4, pp. 585-593
Open Access | Times Cited: 27
Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
Guochen Li, Haiyan Yang, Tengfei Ke, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness
Valentina Bova, Alessia Filippone, Giovanna Casili, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 4032-4032
Open Access | Times Cited: 17
Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma
Ying Bi, Zeng‐Hong Wu, Fei Cao
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease
Chao-Hsien Chen, Renee L. Chin, Genevieve Hartley, et al.
Neuro-Oncology (2023) Vol. 25, Iss. 8, pp. 1415-1427
Open Access | Times Cited: 8
A2AR as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma
Soumaya Rafii, Amina Ghouzlani, Oumayma Naji, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6688-6688
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top